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Critical cell surface immunoreceptors downregu-
lated during HIV infection have previously been iden-
tified using non-systematic, candidate approaches.
To gain a comprehensive, unbiased overview of
how HIV infection remodels the T cell surface, we
took a distinct, systems-level, quantitative proteomic
approach. >100 plasma membrane proteins, many
without characterized immune functions, were
downregulated during HIV infection. Host factors tar-
geted by the viral accessory proteins Vpu or Nef
included the amino acid transporter SNAT1 and the
serine carriers SERINC3/5. We focused on SNAT1,
a b-TrCP-dependent Vpu substrate. SNAT1 antago-
nism was acquired by Vpu variants from the lineage
of SIVcpz/HIV-1 viruses responsible for pandemic
AIDS. We found marked SNAT1 induction in acti-
vated primary human CD4+ T cells, and used Con-
sumption and Release (CoRe) metabolomics to
identify alanine as an endogenous SNAT1 substrate
required for T cell mitogenesis. Downregulation of
SNAT1 therefore defines a unique paradigm of HIV
interference with immunometabolism.
INTRODUCTION
HIV-1 viruses of the AIDS pandemic encode four ‘‘accessory
proteins’’ (Vif, Vpr, Vpu, and Nef) dispensable for viral
replication in vitro, but essential for viral pathogenesis in vivo
(Malim and Emerman, 2008). Vpu and Nef are multifunctional
adaptors that downregulate cell surface proteins to counteract
host-cell restriction and evade the immune response (Haller
et al., 2014; Tokarev and Guatelli, 2011). Targets have typically
been identified using non-systematic, candidate approaches
and include the HIV receptor CD4, the restriction factor teth-Cell Hosterin, and the MHC I molecules HLA-A/B (Tokarev and Guatelli,
2011).
Among primate lentiviruses, a correlation is observed between
viral pathogenicity and expression of Vpu, with CD4+ T cell
decline and progression to AIDS markedly faster in HIV-1 than
HIV-2, and increased mortality in chimpanzees infected with
SIVcpz (Keele et al., 2009). Vpu induces substrate-specific
ubiquitination of CD4 and tetherin through recruitment of the
SCF-b-TrCP E3 ligase complex via a constitutively phosphory-
lated phosphodegron in its cytoplasmic tail (Douglas et al.,
2009; Margottin et al., 1998; Mitchell et al., 2009). In the SIV-
HIV (SHIV) macaque model of HIV, CD4+ T cell loss is abrogated
by deletion of Vpu, scrambling of its transmembrane domain, or
mutation of its b-TrCP-binding phosphodegron (Hout et al.,
2005; Singh et al., 2003; Stephens et al., 2002). This effect is un-
likely to be attributable to loss of Vpu-mediated downregulation
of macaque CD4 or tetherin because CD4 is also efficiently
downregulated by Nef, and pig-tailed macaque tetherin is antag-
onized by SIVmac Nef, but not by HIV-1 Vpu (Zhang et al., 2009).
Together, these data point to the existence of additional, biolog-
ically important, b-TrCP-dependent Vpu substrates.
In this study, we combine plasma membrane enrichment
through selective aminooxy-biotinylation (Plasma Membrane
Profiling; PMP) with TandemMass Tag (TMT) and Stable Isotope
Labeling by Amino Acids in Cell Culture (SILAC)-based quantita-
tive proteomics to describe global changes in the cell surface
landscape of an HIV-infected T cell, including expression time
courses of >800 plasma membrane proteins (Weekes et al.,
2013, 2014). Our unbiased, comprehensive analysis reveals
downregulation of >100 HIV-1 targets, particularly proteins
involved in cell adhesion, leukocyte activation, and transmem-
brane transport, and is presented as a searchable database to
facilitate data mining.
In addition to their known substrates, we show that Vpu is
necessary and sufficient for b-TrCP-dependent degradation of
the amino acid transporter SNAT1, and Nef is sufficient for
downregulation of the serine carriers SERINC3 and SERINC5.
We apply an unbiased, CoRe metabolomic approach to identify
the non-essential amino acid alanine as an endogenous SNAT1& Microbe 18, 409–423, October 14, 2015 ª2015 The Authors 409
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Figure 1. TMT-Based Proteomic Time Course of Plasma Membrane Protein Expression in HIV-1-Infected Cells
(A) Workflow of TMT-based 6-plex PMP time course experiment. In subsequent figures, time points 1–5 show plasma membrane protein expression 0, 6, 24, 48,
and 72 hr after HIV-1 infection (where 0 hr = uninfected cells), and time point 6 shows plasma membrane protein expression 72 hr after HIV-1 infection in the
presence of reverse transcriptase inhibitors (RTi). NL4-3-deltaE-EGFP HIV-1 viruses at an MOI of 10 were used for all proteomic experiments.
(B) Comparison of temporal profiles of CD4 and tetherin obtained by proteomic (TMT) versus flow cytometric quantitation. Cells from (A) were stained with anti-
CD4 and anti-tetherin antibodies at the indicated time points and analyzed by flow cytometry. Relative abundance is expressed as a fraction of maximum TMT
reporter ion or fluorescence intensity. For linear regression, log2(fold change compared with uninfected cells) is shown.
(C) Temporal profiles of previously reported targets for HIV-mediated downregulation.
(legend continued on next page)
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substrate in primary human CD4+ T cells, and show that extra-
cellular alanine is critical for T cell mitogenesis. Restricting
alanine uptake through Vpu-mediated downregulation of
SNAT1 therefore represents a viral strategy to regulate immune
cell activation.
RESULTS
Systematic Time Course Analysis of T Cell Surface
Protein Expression during HIV-1 Infection
To gain a comprehensive, unbiased overview of plasma mem-
brane protein regulation by HIV-1, we used PMP to measure
expression levels of cell surface proteins in CEM-T4 T cells in-
fected with HIV-1 (Figure 1A) (Weekes et al., 2013, 2014). By spi-
noculating cells with Env-deficient, VSVg-pseudotyped virus, we
ensured a synchronous, single-round infection, and by using a
multiplicity of infection (MOI) sufficient to infect >90% of cells,
we minimized confounding effects from bystander (uninfected)
cells (Figure S1A). We exploited 6-plex TMT quantitation to
compare plasma membrane protein abundance in uninfected
cells (0 hr), at 4 time points following HIV-1 infection (6, 24, 48,
and 72 hr) and, to control for cellular changes occurring in the
absence of de novo viral gene expression, in cells infected for
72 hr in the presence of reverse transcriptase inhibitors (RTi).
In total, 2,320 proteins were quantitated, including 804 proteins
previously reported to localize to the plasma membrane (Fig-
ure S1B). The complete dataset is shown in interactive Table
S1, which allows generation of temporal profiles for any quanti-
tated genes of interest.
We observed a strong correlation between expression time
courses determined by mass spectrometry and flow cytometry
for CD4 (R2 = 0.98) and tetherin (R2 = 0.90) (Figure 1B), saw
marked time-dependent depletion of cell surface HLA-A, and
confirmed progressive downregulation of other known HIV-1 tar-
gets (CCR7, CD28, NTB-A, SELL, and the tetraspanins CD37/
53/63/81/82) (Figure 1C) (Haller et al., 2014; Lambele´ et al.,
2015; Ramirez et al., 2014; Shah et al., 2010; Swigut et al.,
2001; Vassena et al., 2015). Downregulation of CD71 and the
chemokine receptors is controversial, with our data suggesting
depletion of cell surface CD71, CXCR4, and CCR5 (Figure S1C).
As expected, VSVg levels increased immediately after infection,
then rapidly declined (Figure S1D).
Discovery of Cell Surface Targets Depleted by HIV-1
To identify host factors regulated by HIV-1 without observer bias
based on known biological function, we used the Short Time
Series Expression Miner (STEM) to cluster proteins according
to patterns of temporal expression and identify profiles occurring
more frequently than expected by chance (Figure 1D). The most
enriched profile comprised 134 proteins showing progressive
time-dependent downregulation, abolished by reverse tran-
scriptase inhibitors (Cluster #35; p = 1078). Proteins in this
cluster, which include CD4, tetherin, and HLA-A, represent
candidate HIV-1 cell surface targets (Table S2).(D) Identification of enriched temporal profiles by STEM. Model temporal profiles
Each box includes a profile identification number (top left) and an unadjusted p va
than expected by chance alone (Bonferroni-adjusted p values < 0.05).
See also Figure S1 and Tables S1 and S2.
Cell HostWe validated these candidates in an independent infection
time course experiment using SILAC as an alternative quantita-
tive proteomic approach (Figures 2A and 2B) and confirmed
downregulation of a functionally and structurally diverse set of
proteins with available antibody reagents (CD43/47/162 and
NOTCH1) by flow cytometry in CEM-T4s and primary human
CD4+ T cells infected with HIV-1 (Figure S2A).
Functional Analysis of Progressively Downregulated
HIV-1 Targets
To identify biological functions targeted by HIV-1 in an unbiased
fashion, we used the Database for Annotation, Visualization and
Integrated Discovery (DAVID) to determine gene ontology
‘‘molecular function’’ and ‘‘biological process’’ annotations
over-represented in Cluster #35 compared with other quanti-
tated proteins. The cluster was enriched for terms relating to
cell adhesion, leukocyte activation, and transmembrane trans-
port. These categories intersect processes known to be modu-
lated by HIV-1 and provide a framework for interpreting both
previously identified and novel HIV-1 targets. We therefore
mined our data for downregulated proteins with closely related
functions (Figures 2C–2F and Table S3).
Cell adhesion molecules regulate leukocyte trafficking and NK
cell killing. Modulation of lymphocytemigration through targeting
of SELL and CCR7 (Figure 1C) is proposed to facilitate HIV-1 im-
mune avoidance (Ramirez et al., 2014; Vassena et al., 2015), and
downregulation of NTB-A (Figure 1C) protects HIV-infected cells
from NK cell lysis (Shah et al., 2010). We now show that HIV-1
also downregulates NCR3LG1 (B7H6; Figure 2D), a ligand for
the NK activating receptor NKp30 found on activated monocytic
cells in vivo (Brandt et al., 2009; Matta et al., 2013). Flow cytom-
etry confirmed reduced Ig-NKp30 binding to HIV-1-infected
CEM-T4 cells (Figure S2B).
HIV-1 replication is critically dependent on the activation state
of infected cells, and the virus employs multiple strategies to
modulate T cell activation and maximize replication in vivo
(Abraham and Fackler, 2012). Attention has focused on downre-
gulation of CD3 by Nef variants of non-pathogenic SIVs, attenu-
ated in HIV-1 Nef (Schindler et al., 2006). Conversely, our data
revealed downregulation of numerous other immunoreceptors
with important functions in T cell activation (Figure 2E), along
with a range of transmembrane transporters with no known roles
in the immune system, particularly amino acid transporters (Fig-
ure 2F). Since T cell activation requires profound upregulation in
amino acid metabolism (Wang et al., 2011), we predict that these
proteins have important, but unrecognized, functions in T cell
biology.
Systematic Plasma Membrane Proteomic Analysis of
HIV-1 Accessory Proteins Vpu and Nef
Depletion of most known HIV-1 cell surface targets has been
attributed to Vpu and/or Nef (Haller et al., 2014; Tokarev
and Guatelli, 2011). To assign downregulation of proteins in
Cluster #35 to particular viral genes, we applied an unbiased,(black) and matched experimental protein expression profiles (red) are shown.
lue (bottom left). Colored boxes indicate model profiles assigned more proteins




Figure 2. SILAC-Based Proteomic Validation and Functional Analysis of Cell Surface Targets Downregulated by HIV-1
(A) Workflow of SILAC-based 3-way PMP time course experiment.
(B) Validation of HIV-1 targets (upper panel) and comparison between SILAC- and TMT-based time course experiments (lower panel). Log2(fold change
compared withmock/uninfected cells) at 24, 48, and 72 hr is shown for proteins fromCluster #35 (red) versus all other quantitated proteins (gray). Downregulation
by HIV-1 is indicated by dotted arrows. Proteins identified by >1 unique peptide in both TMT and SILAC experiments are shown. Crosses indicate mean values.
*p < 0.05; ***p < 0.001.
(legend continued on next page)
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systematic approach to define Vpu and Nef substrates. SILAC-
based PMP was used to compare expression levels of cell
surface proteins in CEM-T4s infected with either Vpu- or Nef-
deficient viruses (Figures 3A and S3A), or transduced with Vpu
or Nef as single genes (Figures 3B and S3B). As positive controls,
we found that Vpu depleted cell surface CD4 and tetherin, while
Nef depleted cell surface CD4 and HLA-A (Figures 3A and 3B).
Surprisingly, many HIV-1 cell surface targets were downregu-
lated efficiently by both Vpu- and Nef-deficient viruses and not
by overexpression of Vpu and Nef as single genes, suggesting
Vpu- and Nef-independent mechanisms.
Targeting of Amino Acid Metabolism by Vpu and Nef
As well as their known targets, we found Vpu to be both neces-
sary and sufficient for downregulation of the amino acid trans-
porter SNAT1 (Figures 2F and 3A–3B), and Nef to be sufficient
for downregulation of the serine carriers SERINC3 and SERINC5
(Figures 2F and 3A–3B). This effect was specific within the
SERINC family, because SERINC1 was induced rather than
downregulated (Figure S1E).While this manuscript was in prepa-
ration, SERINC3 and SERINC5 were independently identified as
HIV-1 restriction factors using orthogonal approaches (M. Piz-
zato, personal communication; H.Gottlinger, personal communi-
cation).We confirmed restriction of infectiousHIV-1 viral produc-
tion by SERINC5, antagonized by Nef (Figure S3C). Conversely,
SNAT1 does not act as an HIV-1 restriction factor (Figure S3D).
Instead, we hypothesized that antagonism of SNAT1-dependent
amino acid transport by Vpu may modulate T cell activation.
We confirmed Vpu-dependent depletion of endogenous
SNAT1 from the plasma membrane of transduced cells by
confocal and total internal reflection (TIRF) microscopy (Figures
S4A and S4B). As well as decreased expression at the cell sur-
face, depletion of total SNAT1 was seen by immunoblot of
CEM-T4s infected with WT or Nef-deficient HIV-1, but not with
Vpu-deficient virus (Figures 3C, lanes 2–4, 3D, lanes 2 and 4,
and S4C), and by immunoblot of CEM-T4s transduced with
Vpu, but not Nef (Figure 3E, lane 5).
Previous studies have suggested that SNAT1 is predominantly
expressed in the CNS (Gu et al., 2001; Varoqui et al., 2000). We
found SNAT1 protein to be poorly expressed in resting primary
human CD4+ T cells but dramatically induced following mito-
genic T cell stimulation (Figures 3F, lanes 2–5, and 3G, panel 2).
Furthermore, Vpu depletes SNAT1 from activated primary hu-
man CD4+ T cells both in the context of viral infection (Figures
S4D and S4E) and as a single gene in transduced cells purified
by Antibody-Free Magnetic Cell Sorting (AFMACS; Figures 3G,
panel 5, 3H, lane 5, and S4F) (Matheson et al., 2014).
Ubiquitination and b-TrCP-Dependent Endolysosomal
Degradation of SNAT1
To probe the mechanism of Vpu-mediated SNAT1 depletion, we
confirmed that Vpu binds endogenous SNAT1 (Figure 4A, lanes 2(C) Gene ontology ‘‘molecular function’’ and ‘‘biological process’’ terms enriched
adjusted p values < 0.05 and containing terms with Bonferroni-adjusted p values
(D–F) Temporal profiles of downregulated proteins associated with cell adhesio
quantitation and time points are as for Figures 1B–1C. Proteins exhibiting >2-f
experiments are shown, and proteins subsequently validated using flow cytome
See also Figure S2 and Table S2.
Cell Hostand 4) and leads to SNAT1 ubiquitination (Figure 4B, lane 5). As
with CD4 and tetherin, downregulation of SNAT1 is rescued by
mutation of the Vpu phosphodegron responsible for b-TrCP
recruitment (S52, 56A) (Figures 3G, panel 6, 3H, lane 6, 4F,
and S5A) and by RNAi-mediated depletion of b-TrCP (Figure 4C,
lane 3).
Vpu mediates degradation of CD4 by hijacking the endo-
plasmic reticulum-associated degradation (ERAD) pathway
(Margottin et al., 1998; Schubert et al., 1998) and antagonizes
tetherin by co-opting the endolysosomal degradative pathway
(Douglas et al., 2009; Mitchell et al., 2009). SNAT1 degradation
is rescued by incubation with vacuolar ATPase inhibitors, but
not proteasome inhibitors (Figure 4D, lanes 5 and 6), and by
RNAi-mediated depletion of TSG101 (Figure 4E, lane 3), sug-
gesting that, as for tetherin, SNAT1 is degraded in endolyso-
somes by the ESCRT machinery.
Downregulation of tetherin is abolished by substitution of
conserved amino acid residues W22 or A14 in the trans-
membrane domain of Vpu, and W22 is also critical for
downregulation of CD4 (Vigan and Neil, 2010). While the
W22A mutation abolished downregulation of all 3 Vpu sub-
strates, SNAT1 and CD4 downregulation were preserved
in the presence of the A14L mutation (Figure 4F, lane 4, and
Figure S4A). The same pattern of SNAT1 downregulation
was observed with equivalent mutations in a patient-derived
Vpu (Figure S5B) and with Vpu mutants in the context of viral
infection (Figure S5C). The pathway for SNAT1 degradation
by Vpu therefore shares the cellular machinery used for
antagonism of tetherin but occurs independently of tetherin
downregulation and may be dissociated from it by the A14L
mutation.
CoReMetabolomic Analysis of SNAT1-Depleted Primary
Human CD4+ T Cells
When overexpressed in vitro, SNAT1mediates uptake of a range
of small neutral amino acids (Gu et al., 2001; Varoqui et al., 2000).
Transport by SNAT1 is Na dependent and sensitive to competi-
tion by the model substrate a-methylaminoisobutyric acid
(MeAIB), a specific inhibitor of amino acid transport System A
(Mackenzie and Erickson, 2004). Based on its functional charac-
teristics and pattern of expression, SNAT1 has primarily been
considered a neuronal glutamine transporter (Chaudhry et al.,
2002).
To identify endogenous SNAT1 substrates in primary human
CD4+ T cells in an unbiased fashion, we combined an ‘‘activa-
tion-rest’’ strategy for shRNA knockdown (Monroe et al., 2014)
with Consumption and Release (CoRe) metabolomics (Jain
et al., 2012) (Figure 5A). Pure populations of transduced cells ex-
pressing control or SNAT1-specific shRNAs were generated by
AFMACS (Figures 5B and S6A) (Matheson et al., 2014). After
resting for 7–10 days, control and SNAT1-depleted cells were
re-stimulated using CD3/CD28 Dynabeads. A marked reductionamong proteins from Cluster #35. DAVID functional annotation clusters with
< 0.05 are shown. Further details are included in Table S3.
n (D), leukocyte activation (E), and transmembrane transport (F). Proteomic
old downregulation compared with uninfected cells in both TMT and SILAC
try or immunoblot are underlined.
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Figure 3. Proteomic Analysis of Vpu and Nef Targets and Identification of SNAT1 as a Vpu Substrate
(A and B) SILAC-based quantitation of plasma membrane proteins in cells infected with Vpu-deficient (y axis) versus Nef-deficient (x axis) HIV-1 viruses (A)
and cells transduced with Vpu (x axis) versus Nef (y axis) as single genes (B). Log2(fold change compared with uninfected [A] or GFP-transduced [B] cells)
(legend continued on next page)
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Figure 4. Mechanism of SNAT1 Depletion
by Vpu
(A) Interaction of SNAT1with Vpu. HeLa cells stably
transducedwith Vpu-HAwere immunoprecipitated
with anti-SNAT1 (G63; first panel) or anti-HA
(second panel) antibodies and immunoblotted with
anti-SNAT1 (H60) or anti-Vpu antibodies. Un-
transduced HeLas transfected with SNAT1-spe-
cific siRNA were included as controls.
(B) Ubiquitination of SNAT1 by Vpu. HeLa cells
stably transduced with Vpu-HA were either
immunoblotted with anti-SNAT1 (H60) and anti-
ubiquitin antibodies (first panel) or immunoprecip-
itated with anti-SNAT1 (G63) antibody, re-immu-
noprecipitated with anti-SNAT1 (H60) antibody,
and immunoblotted with anti-SNAT1 (H60) and
anti-ubiquitin antibodies (second panel). Un-
transduced HeLas transfected with SNAT1-
specific siRNA were included as controls.
Ubiquitinated SNAT1 in control (blue arrow) and
Vpu-expressing (red arrow) HeLas is highlighted.
(C) b-TrCP-dependent depletion of SNAT1. HeLa
cells stably transduced with Vpu-HA were trans-
fected with control or b-TrCP-specific siRNA then
immunoblotted.
(D and E) SNAT1 depletion via an endolysosomal
pathway. HeLa cells stably transduced with Vpu-
HA were either treated with MG132, lactacystin,
concanamycin, or bafilomycin (D) or transfected
with control or TSG101-specific siRNA (E) then
immunoblotted.
(F) Molecular determinants of SNAT1 down-
regulation. Jurkats stably expressing Vpu WT or
indicated Vpu mutants were immunoblotted. Cells
transduced with empty vector (blue), Vpu WT (red),
and Vpu A14L (pink) are highlighted. The same
cells stained with anti-CD4 or anti-tetherin anti-
bodies and analyzed by flow cytometry are shown
in Figure S5A.
See also Figure S5.in proliferation of SNAT1-depleted cells was observed (Figures
5C and S6A). Culture supernatants were sampled at baseline,
24, and 48 hr, and extracellular metabolite fluxes were calculated
on a per-cell basis. In total, data for consumption and release of
126 metabolites, including 19 natural amino acids, were used to
derive CoRe metabolomic profiles of control and SNAT1-is shown for proteins from Cluster #35. Figures S3A and S3B selectively enlarg
peptide are shown.
(C) SNAT1 depletion by HIV-1 infection. CEM-T4s infected withWT NL4-3-deltaE-
indicated time points. An MOI of 10 was used, and infection controls are shown
(D) Rescue of SNAT1 in the absence of Vpu. CEM-T4s infectedwithWT, Vpu-defic
48 hr. An MOI of 10 was used, and infection controls are shown in Figure S4C.
(E) SNAT1 depletion by Vpu. CEM-T4s stably transduced with GFP, Vpu, or Nef w
with control or SNAT1-specific shRNAs were included as controls.
(F) SNAT1 induction in activated primary T cells. Primary human CD4+ T cells ac
points.
(G and H) SNAT1 depletion by Vpu in activated primary T cells. Primary human CD
transduced with the indicated shRNA or Vpu constructs. After purification by AF
Dynabeads and immunoblotted (G) or analyzed by confocal microscopy (H) at 4
See also Figures S3 and S4.
Cell Hostdepleted cells. Principal component analysis readily distin-
guished these profiles, particularly at 48 hr (Figure 5D, upper
panels). Surprisingly, across all measured metabolites, the
most significant difference was in net alanine release, with no dif-
ference in net glutamine consumption (Figure 5D, middle and
lower panels).e the lower left quadrant of each scatterplot. Proteins identified by >1 unique
EGFP HIV-1 virus in the presence or absence of RTi were immunoblotted at the
in Figure S4C.
ient, or Nef-deficient HIV-1 NL4-3-deltaE-EGFP viruseswere immunoblotted at
ere immunoblotted. Untransduced CEM-T4s and CEM-T4s stably transduced
tivated with CD3/CD28 Dynabeads were immunoblotted at the indicated time
4+ T cells were activated with CD3/CD28 Dynabeads and mock transduced or
MACS (Figure S4F), cells were either rested or re-stimulated with CD3/CD28
8 hr.




Figure 5. CoRe Metabolomics of Proliferating T Cells and Identification of Alanine Transport by SNAT1
(A) Workflow of CoRe metabolomics experiment.
(B) SNAT1 knockdown for CoRe metabolomics experiment. Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and mock transduced or
transduced with the indicated shRNAs. After purification by AFMACS (Figure S6A), cells were either rested or re-stimulated with CD3/CD28 Dynabeads, then
immunoblotted at 48 hr.
(legend continued on next page)
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Alanine Transport by Endogenous SNAT1 in T Cells
While attention has focused on glutamine, alanine is the paradig-
matic substrate for System A amino acid transport (Oxender and
Christensen, 1963) and has consistently been found to be a high-
affinity substrate for SNAT1 in overexpression studies (Gu et al.,
2001; Mackenzie and Erickson, 2004; Varoqui et al., 2000). We
therefore hypothesized that the increase in net alanine release
caused by SNAT1 depletion may be explained by a decrease
in SNAT1-mediated alanine uptake. To test this, 3H-alanine
transport was measured directly in AFMACS-purified primary
human CD4+ T cells depleted of SNAT1 by expression of a
SNAT1-specific shRNA (Figure 5E) or wild-type Vpu (Figure 5F).
Whereas alanine uptake in control T cells was markedly reduced
by the System A transport inhibitor MeAIB, this effect was abol-
ished in SNAT1-depleted T cells (Figures 5E and 5F), confirming
alanine transport by endogenous SNAT1.
Critical Requirement for Extracellular Alanine in T Cell
Mitogenesis
Since alanine is both a non-essential amino acid and excreted by
proliferating cells (Jain et al., 2012), including lymphocytes (Fig-
ure 5D, lower panels), it appears paradoxical to suggest that a
reduction in alanine uptake could result in the mitogenic
defect observed in T cells depleted of SNAT1. Nonetheless,
we observed a dose-dependent increase in proliferation of
CEM-T4 and Jurkat T cells cultured in increasing alanine con-
centrations (Figure S7A), and a supply of exogenous alanine is
required for optimal lymphocyte proliferation in response to
PHA (Chuang et al., 1990; Rotter et al., 1979).
We investigated this requirement in primary human CD4+
T cells by activating cells with CD3/CD28 Dynabeads in media
supplemented with increasing alanine concentrations. A clear
dose response in proliferation from 0 to 0.1 mM was observed
(Figure 6A). Furthermore, the effect of increasing alanine con-
centration was inhibited by MeAIB in a dose-dependent fashion,
supporting a role for System A transport in alanine uptake (Fig-
ure 6B). Interestingly, exogenous alanine had no effect on the
expression of the early T cell activation markers CD69 and
CD25 (Figure S7B). The same dissociation of proliferation from
early activation has been reported for T cells stimulated in the
absence of glutamine (Carr et al., 2010).
Contribution of Extracellular Alanine to the Free
Intracellular Amino Acid Pool
To explain the requirement for exogenous alanine in T cell mito-
genesis, we hypothesized that bidirectional transport of alanine(C) Defective proliferation of SNAT1-depleted primary T cells. Re-stimulated cel
indicated time points using CytoCount beads. Data were obtained in triplicate. **p
cytometry (Figure S6B).
(D) CoRemetabolomic analysis of control and SNAT1-depleted primary T cells. Me
MS at baseline, 24, and 48 hr. Data were obtained in triplicate, and Principal comp
by control and SNAT1-depleted cells (upper panels). 95% confidence regions
metabolites at 48 hr are shown on a negative log scale (middle panel). Net consum
of 1 (lower panels). **p < 0.01.
(E and F) Impaired alanine uptake by primary T cells depleted of SNAT1 by shRNA
CD28Dynabeads and uptake (counts perminutes; CPM) of 3H-alanine measured
is included as a control, and MeAIB-inhibitable uptake is highlighted (black arrow
are shown in gray. **p < 0.01.
See also Figure S6.
Cell Hostat the plasma membrane could result in both uptake of extracel-
lular alanine and net alanine excretion (Figure S7C). We therefore
measured the size of the free intracellular alanine pool of primary
human CD4+ T cells re-stimulated with CD3/CD28 Dynabeads
and resuspended in media either lacking alanine or supple-
mented with a physiological alanine concentration (Figures 6C
and S7D). Intracellular alanine levels were markedly reduced
by extracellular alanine depletion, but increased by extracellular
alanine supplementation, an effect abolished in the presence of
MeAIB. These observations confirm bidirectional flux of alanine
across the plasma membrane, resulting in equilibration of intra-
cellular and extracellular alanine concentrations, with alanine up-
take mediated by System A transport.
The free intracellular alanine pool may be filled by de novo syn-
thesis through transamination of pyruvate, by release of alanine
from proteins by proteasomal or lysosomal degradation, or by
uptake of extracellular alanine. To formally distinguish these
possibilities, and assess their relative contributions, we resus-
pended washed cells in media supplemented with physiological
levels of heavy isotopologue-labeled 13C6-glucose and 15N-
alanine (Figure 6D). The free intracellular alanine pool was rapidly
reconstituted by extracellular 15N-alanine, an effect markedly in-
hibited by MeAIB, with little contribution from unlabeled alanine
or alanine generated from 13C-glucose-derived pyruvate (Fig-
ures 6E and S7D). Conversely, almost all lactate released from
cells was derived from glycolysis of 13C6-glucose (Figures 6F).
Finally, MeAIB-inhibitable transamination of 15N-alanine to
15N-glutamate was observed (Figure S7E). Extracellular alanine
is therefore rapidly taken up by System A transport in primary
human CD4+ T cells and incorporated into the wider cellular
metabolite pool.
Modulation of T Cell Mitogenesis by SNAT1
Downregulation in HIV-1 Infection
As a functional readout for SNAT1 downregulation in the context
of viral infection, we examined the effect of Vpu expression on
proliferation of primary human CD4+ T cells. Similar to transduc-
tion with SNAT1 shRNA, lentiviral delivery of WT Vpu (but not the
Vpu S53, 57A phosphodegron mutant) retarded T cell prolifera-
tion (Figure S7F). Remarkably, despite antagonism of cell-cycle
progression by Vpr (Malim and Emerman, 2008), and Vpu-inde-
pendent modulation of a range of mitogenic cell surface proteins
(Figure 2E), we also observed a significant reduction in prolifera-
tion of T cells infected with WT HIV-1, as compared with Vpu-
deficient or Vpu S53, 57A phosphodegron mutant viruses
(Figure 6G).ls from (B) were seeded at equal densities and viable cells enumerated at the
< 0.01. No difference in cell size between the two populations was seen by flow
tabolite compositions of culture supernatants from (C) were determined by LC-
onent analysis was used to compare net consumption or release of metabolites
are shown. p values for differences in consumption or release of individual
ption or release of alanine and glutamine is shown scaled to amaximumchange
(E) or Vpu (F). Cells from Figures 3G–3H were re-stimulated for 48 hr with CD3/
at time points from 30 s to 5min. 3H-alanine transport in the presence ofMeAIB
s). 95% confidence bands on linear regression lines (indicating rates of uptake)





Figure 6. Requirement for Extracellular Alanine in T Cell Mitogenesis
(A) Dose-dependent proliferation of primary T cells in response to exogenous alanine. Primary human CD4+ T cells were stained with CFSE, stimulated with CD3/
CD28 Dynabeads in media supplemented with alanine at the concentrations indicated, and analyzed by flow cytometry after 120 hr (green filled histograms).
Peaks are labeled by division number, and unstimulated cells were included as a control (black dotted lines). Representative data from three independent ex-
periments are shown.
(B) Dose-dependent inhibition of primary T cell proliferation by MeAIB. Primary human CD4+ T cells were stimulated with CD3/CD28 Dynabeads in media
supplemented with alanine andMeAIB at the concentrations indicated. Viable cells were enumerated using CytoCount beads after 72 hr and numbers expressed
as a fraction of the maximum.
(C) Regulation of free intracellular alanine pool by SystemA-dependent alanine uptake. Primary humanCD4+ T cells were expanded, rested, and re-stimulated for
48 hr with CD3/CD28 Dynabeads. Cells were then resuspended in media supplemented with alanine at the concentrations indicated in the presence or absence
(legend continued on next page)
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SNAT1 Downregulation by Vpu Variants of Pandemic
HIV-1 Viruses
HIV-1 viruses form three main groups, each representing a
separate transmission of chimpanzee SIVcpz or gorilla SIVgor
to humans: M (or Main, responsible for the AIDS pandemic),
O (or Outlier), and N (or New or Non-M, Non-O). Group M
viruses are responsible for greater than 90% of all HIV infec-
tions and cluster into genetically distinct clades, of which the
most widespread are A (East Africa), B (Europe and North
America), and C (Southern Africa) (Hemelaar et al., 2011).
Among non-human primates, Vpu is found in viruses of the
SIVcpz lineage (including HIV-1 and SIVgor), as well as more
distantly related guenon monkey viruses (SIVgsn, SIVmus,
and SIVmon).
To explore the phylogenetic history of Vpu-mediated SNAT1
downregulation, we generated a stable 293T cell line expressing
SNAT1-FLAG and CD4 and compared the effects of different
Vpu-IRES-GFP constructs. CD4 downregulation is widely
conserved and therefore represents a positive control for func-
tional Vpu expression (Sauter et al., 2009). As expected, whereas
NL4-3 Vpu (but not Vpu S52A) downregulated both CD4 and
SNAT1-FLAG, Nef only downregulated CD4 (Figure 7A). Deple-
tion of cell surface SNAT1-FLAG was conserved across all 6
HIV-1 clade A, B, and C Vpu variants tested (Figures 7A and
7B), but restricted to the SIVcpz Ptt lineage giving rise to
pandemic HIV-1 group M viruses (Figure 7C). The ability of Vpu
to downregulate SNAT1 has therefore been acquired recently
and may be critical for the in vivo replication or enhanced path-
ogenicity of HIV-1 viruses.
DISCUSSION
In this study, we provide a comprehensive, unbiased temporal
map of the cell surface of an HIV-1-infected T cell. Our plasma
membrane proteomic approach captures transcriptional and
post-transcriptional effects, including protein sequestration
and redistribution, and is not limited to known T cell immunore-
ceptors (Weekes et al., 2014). The study of cell surface proteins
downregulated by viruses has uncovered important areas of im-
munobiology, and manipulation by HIV-1 therefore suggests
host factors with unsuspected functions in both viral pathogen-
esis and cellular physiology. Downregulation is unlikely to reflect
a non-specific cellular response to productive viral infection
because plasma membrane proteins depleted by HIV-1 exhibit
contrasting temporal regulation in cells infected with human
cytomegalovirus, even within protein families (Figures S1F and
S1G) (Weekes et al., 2014).of MeAIB. Abundance of free intracellular alanine at baseline and 60 min is expres
are shown for data obtained in triplicate. No difference in cell size was observed
(D–F) Reconstitution of free intracellular alanine pool by extracellular alanine. Wa
5.6 mM 13C6-glucose and 0.5 mM 15N-alanine (D) in the presence or absence of
supernatant lactate (F) at the indicated time points are expressed as a fraction of
obtained in triplicate. No difference in cell size was observed in the presence or
(G) Defective proliferation of primary T cells depleted of SNAT1 by HIV-1. Primary
CD28 Dynabeads, infected with the indicated NL4-3 Vpu 2_87 HIV-1 viruses at an
Peaks are labeled by division number, and unstimulated cells are included as a con
(p24) cells are shown. Mean percent of infected cells in each generation from
indicate SEM. **p < 0.01.
See also Figure S7.
Cell HostAlong with CD4 and tetherin, our data identify SNAT1 as the
third b-TrCP-dependent Vpu substrate. Other Vpu targets
have been proposed, based on candidate approaches: NTB-A,
CCR7, CD1d, PVR, SELL, and the tetraspanins CD37/53/63/
81/82 (Haller et al., 2014; Lambele´ et al., 2015; Matusali et al.,
2012; Moll et al., 2010; Ramirez et al., 2014; Shah et al., 2010;
Vassena et al., 2015). In general, the mechanisms are not
b-TrCP dependent, remain poorly characterized, and may be in-
direct. Furthermore, the magnitude of downregulation reported
has been modest, which may contribute to less-robust pheno-
types (Sato et al., 2012). Compared with these targets, our sys-
tematic analysis suggests that downregulation of CD4, tetherin,
and SNAT1 is qualitatively distinct (Figure S3E), reflecting
recruitment of b-TrCP and hijack of enzymatic ubiquitin-medi-
ated degradation. Together with downregulation of CD4,
MHC-I, SERINC3, and SERINC5 by Nef, we therefore define a
more limited group of highly downregulated HIV-1 accessory
protein targets.
Vpu and Nef co-operate in the downregulation of CD4 and
tetherin, and loss of function in one gene may be compensated
by gain of function in the other (Sauter et al., 2009). The Nef pro-
teins of HIV-2 and most SIVs are able to modulate T cell activa-
tion by downregulating CD3 from the surface of infected cells,
but Nef has lost this ability in most Vpu-containing viruses. Vpu
has therefore been suspected to modulate T cell activation via
an alternative pathway (Kirchhoff, 2009).We focused on downre-
gulation of SNAT1 both because it is a direct Vpu target and
because the importance of amino acid transport in regulating
T cell activation is increasingly recognized (Nakaya et al., 2014;
Sinclair et al., 2013). Furthermore, while many transporters are
poorly characterized multi-pass transmembrane proteins with
few reliable reagents, their plasma membrane location makes
them potentially druggable therapeutic targets, and inhibitors
already exist for many biochemically defined transport systems.
Induction of SNAT1 mRNA correlates with increased gluta-
mine uptake during activation of murine T cells (Carr et al.,
2010), but other candidate glutamine transporters are also
induced (Nakaya et al., 2014; Wang et al., 2011), and pre-
genomic studies attributed lymphocyte glutamine transport to
Systems ASC, L, and N, not System A (Segel, 1992). We there-
fore used an unbiased systematic approach to identify SNAT1
substrates in primary humanCD4+ T cells. Measured differences
between alanine fluxes of control and SNAT1-depleted cells
could potentially reflect both direct transport effects and sec-
ondary effects on synthesis or utilization. Alanine may be
synthesized by transamination of pyruvate and glutamine-
derived glutamate, and re-analysis of data from a previoussed as a fraction of the maximum. Mean values and 95% confidence intervals
between 0 and 0.5 mM alanine (Figure S7D, left panel).
shed cells prepared as in (C) were resuspended in media supplemented with
MeAIB. Abundances of labeled and unlabeled free intracellular alanine (E) and
the maximum. Mean values and 95% confidence intervals are shown for data
absence of MeAIB (Figure S7D, right panel).
human CD4+ T cells were stained with CellTrace Violet, stimulated with CD3/
MOI of 3, and analyzed by flow cytometry after 120 hr (violet filled histograms).
trol (black dotted lines). Representative data for infected (p24+) and uninfected
four independent experiments are depicted as stacked columns. Error bars
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A B
C
Figure 7. SNAT1 Downregulation by Vpu
Variants from Pandemic HIV-1 Viruses
(A) Screening strategy for SNAT1 downregulation
by naturally occurring Vpu variants. 293Ts stably
expressing SNAT1-FLAG and CD4 were trans-
fected with the indicated pCG-IRES-GFP con-
structs (all based on HIV-1 groupM, clade B, strain
NL4-3 virus) and analyzed by flow cytometry at
36 hr. Target downregulation is indicated by a shift
in the transfected (GFP+) cells toward the lower left
quadrant (red arrows).
(B) SNAT1-FLAG downregulation by Vpu variants
from pandemic HIV-1 group M clade A/B/C vi-
ruses. As for (A), but cells were transfected with
pCG-IRES-GFP constructs encoding Vpu variants
from the indicated strains of HIV-1.
(C) Phylogenetic analysis of SNAT1-FLAG down-
regulation by Vpu variants of HIV-1 and SIV viruses.
As for (A) and (B), but cells were transfected with
pCG-IRES-GFP constructs encoding Vpu variants
from the indicated strains of HIV-1 or SIV and
downregulation of SNAT1-FLAG or CD4 expressed
as ratio of geomean fluorescence intensity between
transfected (GFP+) and untransfected (GFP) cells.
Illustrativephylogenetic relationshipsareshown,and
branch lengths are arbitrary (further details are
included inSupplementalExperimentalProcedures).
HIV-1/M/N/O (HIV-1 group M, N, or O viruses);
SIVcpz Ptt (SIVs infecting central P. t. troglodytes
chimpanzees); SIVcpz Pts (SIVs infecting eastern
P. t. schweinfruthii chimpanzees); SIVgor (gorilla
SIV); SIVguenon (SIVs infecting guenon monkeys).CoRe metabolomic screen of NCI-60 cancer cell lines confirmed
that release of alanine typically correlates with release of lactate
and consumption of glucose and glutamine (Jain et al., 2012).
Conversely, we saw no difference between control and
SNAT1-depleted cells in release of lactate or consumption of
glucose and glutamine (Figures 5D and S6C), suggesting similar
rates of alanine synthesis, and confirmed alanine uptake by
SNAT1 in primary human CD4+ T cells using a formal transport
assay and a concentration of alanine approximating that seen
in vivo.
Alanine is the second most abundant amino acid in human
plasma, but absent from standard media such as RPMI, and
contributed to in vitro cell culture systems by serum supplemen-
tation (Rotter et al., 1979). Despite net excretion, we show that
the concentration of extracellular alanine dramatically impacts
T cell mitogenesis, and uptake of exogenous alanine by System
A transport is critical to maintain the free intracellular alanine
pool. Alanine is a major constituent of mammalian proteins and
may be incorporated into the wider cellular metabolite pool by420 Cell Host & Microbe 18, 409–423, October 14, 2015 ª2015 The Authorstransamination. In addition, bidirectional
transport of alanine at the plasma mem-
brane may be used to drive tertiary active
transport of other amino acids (Nicklin
et al., 2009). The relative significance of
these effects remains to be determined.
While amino acid availability is known to
regulate immune activation in multiple
settings, antagonism of SNAT1 by HIV-1Vpu is a specific example of viral interference with amino acid
immunometabolism.
Modulation of cell surface targets by virusesmay enhance viral
replication directly, in a cell-autonomous fashion, or indirectly,
through effects on non-infected cells or the immune response.
It is difficult to account for indirect effects on virus production
in vivo using in vitro models. For example, tetherin restricts
(Neil et al., 2008) or enhances (Jolly et al., 2010) HIV-1 replication,
depending on the assay used. The significance of tetherin as a
restriction factor is instead proven by conservation of antago-
nism across a range of HIV and SIV viruses, and we therefore
sought analagous genetic evidence for the importance of
SNAT1 in the host-HIV interaction. SNAT1 antagonism was
observed for HIV-1 group M Vpu variants from laboratory-
adapted viruses and primary patient isolates, including a founder
virus strain, X4 and R5 tropic viruses, and related HIV-1 group N
and SIVcpz Ptt Vpu variants. Remarkably, despite the extraordi-
nary sequence diversity of HIV-1, and the potential to dissociate
SNAT1 downregulation from that of CD4 and tetherin, the ability
of Vpu to target SNAT1 is therefore conserved across pandemic
HIV-1 viruses, suggesting a significant selective advantage.
Furthermore, the restriction of SNAT1 downregulation to Vpu
variants from the SIVcpz/HIV-1 lineage suggests a specific role
in the pathogenesis of these viruses.
EXPERIMENTAL PROCEDURES
HIV-1 Infections
For proteomic time course analysis, CEM-T4 T cells were spinoculated with
VSVg-pseudotyped NL4-3-dE-EGFP HIV-1 virus at an MOI of 10, aliquots of
infected cells harvested sequentially at the indicated time points, and dead
cells removed by immunomagnetic depletion prior to PMP.
Plasma Membrane Enrichment and Peptide Labeling
PMPwas performed as previously described (Weekes et al., 2013, 2014) using
23 107 viable cells per condition and a ‘‘one pot’’ oxidation and aminooxy-bio-
tinylation reaction to selectively biotinylate plasma membrane glycoproteins
before immunoprecipitation with streptavidin beads and on-bead tryptic
digestion. For TMT quantitation, cells from each condition were processed
separately, and peptide samples were labeled with TMT reagents before pool-
ing. For SILAC quantitation, cells were pre-labeled by propagation in SILAC
media and pooled prior to processing together.
Proteomics and Data Analysis
Peptide samples were fractionated by high-pH reverse-phase high-pressure
liquid chromatography (HpRP-HPLC) and analyzed by liquid chromatography
coupled to triple-stage (TMT) or tandem (SILAC) mass spectrometry using an
Orbitrap Fusion Tribrid (TMT) or Q Exactive (SILAC) mass spectrometer.
Reporter ions from TMT-labeled peptides were quantitated from an MS3
scan using Proteome Discoverer. SILAC-labeled peptides were quantitated
using MaxQuant.
Primary Cell Knockdowns
Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and
transduced with lentiviral constructs encoding U6-shRNA knockdown and
SFFV-SBP-DLNGFR streptavidin-binding affinity tag cassettes. Transduced
cells were selected with streptavidin Dynabeads then released by incubation
with excess biotin as previously described (AFMACS) (Matheson et al.,
2014). Ethical permission for this project was granted by the Cambridgeshire
2 Research Ethics Committee (REC reference 97/092). Informed written con-
sent was obtained from all of the volunteers included in this study prior to
providing blood samples.
CoRe Metabolomics and Data Analysis
AFMACS-purified primary human CD4+ T cells expressing control or SNAT1-
specific shRNAs were re-stimulated using CD3/CD28 Dynabeads. After 24 hr,
cells were resuspended in 20% conditioned media at equal densities and su-
pernatant samples at baseline, 24, and 48 hr were analyzed by liquid chroma-
tography coupled to mass spectrometry (LC-MS) as previously described
(Jain et al., 2012). To account for differential proliferation, viable cells were
enumerated at each time point and changes in metabolite concentrations
normalized based on average cell numbers.
3H-Alanine Uptake
AFMACS-purified primary human CD4+ T cells expressing control or SNAT1-
specific shRNAs were re-stimulated using CD3/CD2 min8 Dynabeads. After
48 hr, cells were starved to reduce trans-inhibition then resuspended at
37C in Tyrode’s buffer supplemented with 3H-alanine at a final concentration
of 0.5 mM. Aliquots of cells were harvested sequentially over 5 min and uptake
terminated by filtering centrifugation through silicone oil before liquid scintilla-
tion counting.
Free Intracellular Amino Acids
Primary human CD4+ T cells were expanded once and then re-stimulated
using CD3/CD28 Dynabeads. After 48 hr, cells were resuspended in media
supplemented with dialyzed FCS and either unlabeled alanine and glucoseCell Hostor (for stable isotopologue-resolved metabolomics) 15N-alanine and 13C6-
glucose at concentrations of 0.5 mM and 5.6 mM, respectively. Aliquots of
cells were harvested sequentially over 1 hr, and free intracellular amino acids
were extracted from washed cells using dry ice-cold 50% methanol 30%
acetonitrile before analysis by LC-MS. Please see Supplemental Experimental
Procedures for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2015.09.003.
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